Lead Product(s) : Mecasermin Rinfabate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Chiesi and Oak Hill Enter License Agreement for OHB-607 Development
Details : An agreement focuses on developing and commercializing OHB-607 (mecasermin rinfabate), a recombinant IGF-1 for treating complications of extremely premature birth.
Product Name : OHB-607
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
September 01, 2024
Lead Product(s) : Mecasermin Rinfabate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : AX-8
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axalbion Doses First Patient in Phase 2 Study of AX-8 for Chronic Cough
Details : AX-8 is a potent and selective oral agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel, which is being evaluated for the treatment of chronic cough.
Product Name : AX-8
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2024
Lead Product(s) : AX-8
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mecasermin Rinfabate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Oak Hill Bio & Chiesi Group Resume Phase 2 Study of OHB-607 for Bronchopulmonary Dysplasia
Details : OHB-607 is the recombinant form of human insulin-like growth factor-1 (IGF-1). It is being evaluated for the prevention of bronchopulmonary dysplasia in premature infants.
Product Name : OHB-607
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 17, 2024
Lead Product(s) : Mecasermin Rinfabate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Redx Provides Progress Update on RXC007 Clinical Programm
Details : RXC007 is an oral, selective Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Product Name : RXC007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2023
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HEX17
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Thairm Bio
Deal Size : $10.0 million
Deal Type : Financing
Details : The funding will advance the Phase 2 clinical development of Neumifil (sialic acid binding protein), a novel, engineered multivalent Carbohydrate Binding Molecule, for individuals with Chronic Obstructive Pulmonary Disease suffering from virus induced ex...
Product Name : Neumifil
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 06, 2023
Lead Product(s) : HEX17
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Thairm Bio
Deal Size : $10.0 million
Deal Type : Financing
Lead Product(s) : SNG001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The results suggest that HRV was cleared more rapidly in patients treated with SNG001 (Interferon Beta-1a) than placebo with a statistically significant difference in the proportion of patients with detectable HRV in sputum at Day 7 (post hoc analysis).
Product Name : SNG001
Product Type : Protein
Upfront Cash : Inapplicable
July 09, 2022
Lead Product(s) : SNG001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AX-8
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axalbion Announces Positive Findings from PII Study in Chronic Cough with AX-8
Details : Treatment with AX-8 40 mg BID compared to placebo showed a reduction in cough frequency within the first 15 minutes after treatment and lasting for more than 4 hours.
Product Name : AX-8
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 29, 2022
Lead Product(s) : AX-8
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AX-8
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AX-8 is potent and selective oral agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel has a novel mechanism of action targeting the TRPM8 ion channel, help normalize upper airway sensitivity in chronic cough patients.
Product Name : AX-8
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : AX-8
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
Details : Ensifentrine delivered by pMDI met all of the primary and secondary lung function endpoints in the 7 day, Phase 2 clinical trial.
Product Name : Ohtuvayre
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2021
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Acalabrutinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The addition of Calquence to best supportive care (BSC) did not increase the proportion of patients who remained alive and free of respiratory failure. No new safety signal for Calquence was observed in the trials.
Product Name : Calquence
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Acalabrutinib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable